SLNO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Soleno Therapeutics Inc (SLNO) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is trading near its acquisition price of $53, leaving limited upside potential. Additionally, the ongoing lawsuits and weak financial performance further diminish its attractiveness.
The stock is overbought with an RSI of 90.52, and the MACD is positively contracting. The current price of $52.57 is near the resistance level of $53.013, indicating limited room for further price appreciation. The stock has a 60% chance of declining slightly in the next day and week.
The acquisition deal by Neurocrine Biosciences at $53 per share provides a floor for the stock price, reducing downside risk.
Multiple class action lawsuits related to safety concerns in clinical trials and product disclosures. Downgrades by analysts with price targets aligned to the acquisition price, indicating limited growth potential. Weak financial performance with significant YoY declines in net income and EPS.
In Q4 2025, revenue remained flat YoY at $91.73M. However, net income dropped significantly by -176.71% YoY, and EPS fell by -156.69% YoY, indicating poor profitability. Gross margin remained high at 99.06%, but this did not translate into improved earnings.
All recent analyst ratings have downgraded SLNO to Neutral or Hold, with price targets reduced to $53, citing the acquisition deal. Analysts do not expect a superior bid or significant upside from the current price.
